

# BUMRUNGRAD HOSPITAL

## THAILAND / HEALTH CARE SERVICES

BH TB

**HOLD**

FROM BUY

## Seeking operational recovery

- Lower fly-in foreign patient volume this year set to rebound with tourism recovery in 2026 and the new Phuket hospital in 2027.
- Expect 2025 core profit to fall 9%; modest 3-4% growth expected in 2026-27, with downtrend in NPM and ROE over the period.
- Valuation has limited upside, moderate dividend yields.

TARGET PRICE	THB160.00
CLOSE	THB151.50
UP/DOWNSIDE	+5.6%
PRIOR TP	THB220.00
CHANGE IN TP	-27.3%
TP vs CONSENSUS	-16.0%

## KEY STOCK DATA

YE Mar (THB m)	2024	2025E	2026E	2027E
Revenue	25,718	24,679	25,673	27,232
Net profit	7,775	7,088	7,303	7,570
EPS (THB)	9.77	8.91	9.18	9.51
vs Consensus (%)	-	0.2	1.0	1.2
EBITDA	10,265	9,572	10,008	10,512
Recurring net profit	7,798	7,088	7,303	7,570
Core EPS (THB)	9.80	8.91	9.18	9.51
Chg. In EPS est. (%)	-	(10.3)	(9.6)	(11.1)
EPS growth (%)	12.7	(9.1)	3.0	3.6
Core P/E (x)	15.5	17.0	16.5	15.9
Dividend yield (%)	3.4	3.3	3.5	3.6
EV/EBITDA (x)	10.6	11.1	10.3	9.5
Price/book (x)	4.4	3.9	3.6	3.3
Net debt/Equity (%)	(43.1)	(47.2)	(52.0)	(55.9)
ROE (%)	30.4	24.4	22.7	21.5

## Foreign patient wing set to gradually rebound

BH continues to face headwinds from lower fly-in patient volumes, rising competition, and the sluggish Thai economy, affecting revenue intensity. We expect its OPD and IPD patient volumes to decline by 5% y-y in 2025, and gradually recover by 2-3% in 2026-27. Its international patient revenue mix may decline to 64% this year (2024: 66%), then recover by 1ppt annually. The topline may return to the 2024 levels in 2027. Penetration into new source markets like Saudi Arabia holds potential, but material impacts on earnings could remain in the long term.

## 2025 decline, mild growth ahead


We cut our core profit forecast to THB 7.1b (-9% y-y) in 2025, with a 4% drop in revenue and a 1.1ppt decline in EBITDA margin. Changes in patient mix and weaker operating leverage may fluctuate its profit margins. We expect 3-4% earnings growth in 2026-27, assuming its new Phuket hospital's early-stage effect on EBITDA margin in 2027. Core profit and NPM will not likely reach 2024 levels over the next three years.

## Quarterly earnings not yet attractive

We expect BH's 2Q25 core profit at THB1.67b (-4% q-q, -14% y-y), the lowest in eight quarters. This follows lower fly-in patient volumes, mainly from Kuwait and China, and earthquake concerns in Thailand. This is based on THB5.99b in revenue (-2% q-q, -5% y-y) and a 37% EBITDA margin. 1H25 core profit may fall 13% y-y, with a q-q recovery expected in 3Q25, but y-y growth remaining negative due to ongoing challenges.

## Lower our call to Hold

We have reduced our DCF-based target price to THB160 (from THB220) (9.1% WACC, 2% TG), equivalent to 17x 2026E P/E or <-0.5SD below the stock's 5-year historical trading average. BH trades at 16.5x 2026E P/E, in line with the Thai healthcare sector but below regional averages. Despite having the highest ROE and strong margins, both are expected to decline over the next three years. Dividend yield remains moderate at 4%. The new Phuket campus may be a long-term support, while positive developments in foreign visitor arrivals to Thailand and fly-in patient referrals from Kuwait and Saudi Arabia may act as catalysts. With this report, we transfer the coverage of BH to Vatcharut Vacharawongsith.



Share price performance	1 Month	3 Month	12 Month
Absolute (%)	12.6	(10.1)	(38.2)
Relative to country (%)	(0.5)	(12.7)	(34.4)
Mkt cap (USD m)	3,710		
3m avg. daily turnover (USD m)	18.3		
Free float (%)	72		
Major shareholder	Bangkok Insurance (11%)		
12m high/low (THB)	284.00/130.00		
Issued shares (m)	922.70		

Sources: Bloomberg consensus; FSSIA estimates


**Vatcharut Vacharawongsith**

Fundamental Investment Analyst on Securities; License no. 018301  
 vatcharut.v@fssia.com, +66 2646 9969

### Investment thesis

BH's core operations are experiencing pressure from soft fly-in patient volumes, economic slowdown, and rising competition, which may undermine its patient volume this year. International patient revenue should improve from 2026 onwards on the back of normalized strong demand for medical tourism.

BH's EBITDA margin may be fluctuate over the next three years. The new hospital ramp-up in Phuket may cap the profit margin recovery in 2027. We expect mild earnings growth of 3-4% in 2026-27, but still below 2024 levels.

ROE and margins remain above peers but are trending lower. Expansion into new source markets offers upside, but materialized earnings impact may persist in the longer term.


### Company profile

BH is a leading private hospital (580 licensed beds) in the premium segment.

[www.bumrungrad.com](http://www.bumrungrad.com)

### Principal activities (revenue, 2024)


- Thai patient revenue - 33.9 %
- International patient revenue - 65.8 %
- Other revenue - 0.3 %



Source: Bumrungrad Hospital

### Major shareholders

- Bangkok Insurance - 11.0 %
- Thai NVDR - 10.4 %
- UOB Kay Hian (Hong Kong) - 7.8 %
- Bangkok Bank - 6.7 %
- Others - 64.2 %



Source: Bumrungrad Hospital

### Catalysts

Key growth drivers include 1) a new market including patients from Saudi Arabia and China; 2) the new hospital in Phuket, which will unlock growth from the standalone model; and 3) the vital life business (Wellness), which has a high margin compared to traditional healthcare.

### Risks to our call

Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) higher medical fee discount promotions, leading to a weaker EBITDA margin. Upside risks include positive developments in foreign visitor arrivals to Thailand and fly-in patient referrals from Kuwait.

### Event calendar

Date	Event
Jul 2025	2Q25 results announcement

### Key assumptions

	2025E	2026E	2027E
	(%)	(%)	(%)
OPD Volume growth	(5)	2	3
OPD revenue / patient growth	1	2	3
IPD Volume growth	(5)	2	3
IPD revenue / patient growth	1	2	3

Source: FSSIA estimates

### Earnings sensitivity

- For every 1% increase in patient volume, we project 2025 earnings to rise by 2%, and vice versa, all else being equal.
- For every 1% increase in EBITDA margin, we project 2025 earnings to rise by 4%, and vice versa, all else being equal.

Source: FSSIA estimates


## Foreign patient mix to gradually rebound

We believe BH continues to face challenges from a decline in international tourist volumes, intensifying competition, Thailand's ongoing sluggish economy, and the revenue correction from fly-in Kuwaiti patients, all of which are affecting its revenue intensity. We thus assume outpatient and inpatient volumes will decline 5% y-y in 2025, followed by a cautious 2% recovery in 2026, and stronger 3% growth in 2027 – supported by the opening of its new hospital campus in Phuket. We expect that the topline may return to the 2024 peak levels by 2027.

The revenue mix from total international patients may drop to 64% this year (2024: 66%) before gradually increasing by 1ppt per year in 2026–27. We forecast revenue from Middle East patients to reduce by further 10% y-y, contributing 22.5% of BH's total topline in 2025 (2024: 24%). It should turn to recover by 6% y-y with a 23.5% revenue mix in 2026 following a better outlook for Kuwaiti patients and ongoing demand from other countries in the region. Penetration into new source markets such as Saudi Arabia offers long-term potential, though a material earnings contribution is likely to take time to emerge.


The new Bumrungrad International Hospital Phuket, set to open within 2027, is expected to be a key earnings growth driver in the long-term. Of the total 212 registered beds, the secondary care facility may launch its first phase with an initial capacity of 50 beds and plans to ramp up to 150 beds within the same development phase over the next few years. We believe the new campus will benefit from Thailand's growing medical tourism sector, supported by the country's relatively low healthcare costs and strong competitive edge in hospitality services. These advantages position BH to attract high-end patients – including Thai locals, expatriates, and fly-in patients. Our projection assumes the new hospital will deliver improving EBITDA over its second to third year of operations, with BH's overall EBITDA margin expected to expand in 2028.

**Exhibit 1: Revenue breakdown by patient types**




Sources: BH; FSSIA estimates

**Exhibit 2: Revenue per patient**




Sources: BH; FSSIA estimates

Exhibit 3: International patient revenue




Sources: BH; FSSIA estimates

Exhibit 4: Thai patient revenue




Sources: BH; FSSIA estimates

Exhibit 5: Middle East patient revenue




Sources: BH; FSSIA estimates

Exhibit 6: Non-Middle East international patient revenue




Sources: BH; FSSIA estimates

Exhibit 7: Cost savings for medical tourists by country



Source: Patients Beyond Borders

Exhibit 8: Thailand medical tourism market is estimated to grow 10.5% CAGR from 2024 to 2030 (USD b)



Source: Grand View Research

## Forecast cut, mild growth ahead

We revise down our 2025-27 core profit forecasts by 10-11% to reflect weaker international patient revenue and a volatile EBITDA margin, impacted by changes in patient mix, reduced operating leverage, and early-stage operations of the new Phuket hospital set to open in 2027.

We now expect a 2025 core profit of THB7.09b (-9% y-y), on total revenue of THB24.68b (-4% y-y) and an EBITDA margin of 38.8% (-1.1ppt y-y), pressured by declining revenue intensity – mainly among international patients. We expect both OPD and IPD volumes to decline 5%, with revenue per patient rising only 1% from price adjustments.

Looking ahead, we conservatively expect BH's core profit to grow 3% in 2026 and 4% in 2027, supported by a gradual recovery in international tourist arrivals across both Chinese and non-Chinese markets. Total revenue may turn to expand 4-6% over the two-year period, with EBITDA margin rising by 0.2ppt to 39.0% in 2026 and declining 0.4ppt to 38.6% in 2027.


BH's International patient revenue is forecast to fall 7% in 2025 before rebounding 5-8% in 2026-27. Domestic patient revenue is expected to grow 1% in 2025 and accelerate to 3% annually over 2026-27. The company's new hospital in Phuket may be a long-term growth driver, though we think its ramp-up costs are likely to weigh on profitability in the early stage of operations. As such, BH's core profit is unlikely to return to the 2024 peak within 2025–27, and NPM should remain in a downtrend over the period.

### Exhibit 9: Earnings revisions

	Current			Previous			Change (%)		
	2025E	2025E	2027E	2025E	2026E	2027E	2025E	2026E	2027E
OPD patient revenue (THB b)	12.3	12.8	13.6	13.1	13.9	14.6	(5.9)	(7.7)	(6.8)
IPD patient revenue (THB b)	12.3	12.8	13.6	13.1	13.7	14.4	(5.9)	(6.8)	(5.9)
Thai patient revenue (THB b)	8.8	9.1	9.3	9.1	9.4	n/a	(2.9)	(3.8)	n/a
International patient revenue (THB b)	15.8	16.5	17.8	17.1	18.2	n/a	(7.5)	(9.1)	n/a
Revenue (THB b)	24.7	25.7	27.2	26.2	27.7	29.1	(5.9)	(7.3)	(6.4)
EBITDA Margin (%)	38.8	39.0	38.6	40.4	39.9	40.1	(1.6)	(0.9)	(1.5)
Core profit (THB b)	7.1	7.3	7.6	7.9	8.1	8.5	(10.3)	(9.6)	(11.1)


Source: FSSIA estimates

### Exhibit 10: Chinese and non-Chinese visitor arrivals to Thailand



Sources: Ministry of Tourism and Sports (MOTS); FSSIA estimates

### Exhibit 11: BH's EBITDA margin, NPM and ROE



Sources: BH; FSSIA estimates

## 2Q25E preview

We expect BH to post a 2Q25 core profit of THB1.67b, (-4% q-q, -14% y-y). While the post-Ramadan period supported a rebound in patients from Middle Eastern countries, overall international patient volumes were still undermined by the ongoing weakness in Kuwaiti patient revenue (c2% from a previous 6% contribution), fewer Chinese tourists, and concerns over the recent earthquake in Thailand – impacting both revenue and profit margins. High-income fly-in patients from Cambodia (c3% of revenue) continue to seek treatment despite the border unrest. We estimate the 2Q25 topline at THB5.99b (-2% q-q, -5% y-y) with an EBITDA margin of 37% (-0.2ppt q-q, -3.3ppts y-y). Its 1H25 core profit may decline 13% y-y, representing 48% of our full-year forecast.

We expect 3Q25 earnings to improve q-q in the high season for medical care services, but remain lower y-y (likely at a smaller magnitude than in 1Q25-2Q25) primarily due to the slowdown international patient volumes.

### Exhibit 12: BH – 2Q25E preview

	2Q24	3Q24	4Q24	1Q25	2Q25E	---- Change ----		1H24	1H25E	Change	2025E	Change
	(THB m)	(THB m)	(THB m)	(THB m)	(THB m)	(q-q %)	(y-y %)	(THB m)	(THB m)	(y-y %)	(THB m)	(y-y %)
<b>Sales</b>	<b>6,303</b>	<b>6,405</b>	<b>6,473</b>	<b>6,141</b>	<b>5,989</b>	<b>(2)</b>	<b>(5)</b>	<b>12,839</b>	<b>12,129</b>	<b>(6)</b>	<b>24,679</b>	<b>(4)</b>
COGS (incl. depreciation)	(3,008)	(3,089)	(3,259)	(3,040)	(2,964)	(2)	(1)	(6,154)	(6,004)	(2)	(12,215)	(2)
<b>Gross Profit</b>	<b>3,294</b>	<b>3,316</b>	<b>3,214</b>	<b>3,101</b>	<b>3,024</b>	<b>(2)</b>	<b>(8)</b>	<b>6,685</b>	<b>6,125</b>	<b>(8)</b>	<b>12,464</b>	<b>(6)</b>
SG&A	(1,007)	(1,003)	(1,142)	(1,084)	(1,068)	(2)	6	(2,027)	(2,151)	6	(4,126)	(1)
<b>Operating Profit</b>	<b>2,288</b>	<b>2,313</b>	<b>2,072</b>	<b>2,017</b>	<b>1,957</b>	<b>(3)</b>	<b>(14)</b>	<b>4,658</b>	<b>3,974</b>	<b>(15)</b>	<b>8,338</b>	<b>(8)</b>
Net other income	28	41	46	67	45	(33)	61	57	112	96	149	3
Interest income	79	74	66	63	67	6	(15)	140	130	(7)	242	(13)
Interest expense	(2)	(2)	(2)	(2)	(2)	(1)	(3)	(4)	(4)	(3)	(37)	
<b>Pretax profit</b>	<b>2,393</b>	<b>2,426</b>	<b>2,182</b>	<b>2,146</b>	<b>2,067</b>	<b>(4)</b>	<b>(14)</b>	<b>4,852</b>	<b>4,212</b>	<b>(13)</b>	<b>8,692</b>	<b>(8)</b>
Income Tax	(432)	(424)	(279)	(400)	(378)	(5)	(12)	(901)	(778)	(14)	(1,543)	(4)
Share gain/loss from JV	(0)	(0)	(0)	(0)	0			(0)	(0)			
Share gain/loss from associates	(0)	(0)	(0)	0	0			(0)	0		(0)	5
Minority interest	(24)	(12)	(7)	(10)	(20)			(39)	(30)		(61)	6
<b>Core profit</b>	<b>1,937</b>	<b>1,990</b>	<b>1,896</b>	<b>1,736</b>	<b>1,668</b>	<b>(4)</b>	<b>(14)</b>	<b>3,912</b>	<b>3,404</b>	<b>(13)</b>	<b>7,088</b>	<b>(9)</b>
Extraordinaries, GW & FX	(5)	(34)	7	(2)	0			5	(2)		0	
<b>Reported net profit</b>	<b>1,932</b>	<b>1,955</b>	<b>1,903</b>	<b>1,734</b>	<b>1,668</b>	<b>(4)</b>	<b>(14)</b>	<b>3,917</b>	<b>3,402</b>	<b>(13)</b>	<b>7,088</b>	<b>(9)</b>
Outstanding shares (m)	796	796	796	796	796	0	0	796	796	0	796	0
Core EPS (THB)	2.43	2.50	2.38	2.18	2.10			4.92	4.28	(13)	8.91	(9)
EPS (THB)	2.43	2.46	2.39	2.18	2.10			4.92	4.28	(13)	8.91	(9)
COGS (excl. depreciation)	2,742	2,820	2,984	2,784	2,704	(3)	(1)	5,621	5,489	(2)	11,130	(3)
Depreciation	267	269	275	256	260	2	(2)	533	516	(3)	1,086	1
EBITDA	2,582	2,623	2,393	2,340	2,262	(3)	(12)	5,249	4,602	(12)	9,572	(7)
<b>Key ratios</b>	<b>(%)</b>	<b>(%)</b>	<b>(%)</b>	<b>(%)</b>	<b>(%)</b>	<b>(ppt)</b>	<b>(ppt)</b>	<b>(%)</b>	<b>(%)</b>	<b>(ppt)</b>	<b>(%)</b>	<b>(ppt)</b>
Gross margin	52	52	50	50	50	(0)	(2)	52	50	(2)	51	(1)
SG&A/Revenue	16	16	18	18	18	0	2	16	18	2	17	1
EBITDA margin	41	41	37	38	37	(0.2)	(3.3)	41	38	(3)	39	(1)
Net profit margin	31	31	29	28	28	(0)	(3)	31	28	(2)	29	(2)
<b>Operating stats</b>	<b>(y-y %)</b>	<b>(y-y %)</b>	<b>(y-y %)</b>	<b>(y-y %)</b>								
Hospital revenue growth	4	(5)	(1)	(6)								
International patient revenue growth	5	(7)	(6)	(10)								
Thai patient revenue growth	2	(1)	10	1								

Sources: BH; FSSIA estimates

## Valuation sees limited upside

We have lowered our DCF-based target price to THB160 (from THB220) applying a 9.1% WACC and 2% terminal growth. The new target price is equivalent to 17x 2026E P/E and 3.8x 2026E P/BV – representing <-0.5SD and -1.5SD below the stock's 5-year historical trading averages, respectively. The current share price is trading at similar levels, around 16.5x 2026E P/E and 3.6x 2026E P/BV.

While BH trades at a P/E multiple in line with the Thai healthcare sector and below the regional average (30x), its earnings growth outlook also lags behind peers. The company's strength lies in its industry – leading ROE, supported by robust net profit margins, but we expect both metrics may decline over the next three years. Dividend yield remains moderate at around 4%. As such, we downgrade our rating to HOLD (from Buy), expecting a recovery in core profit approaching the peak 2024 levels in the longer term.

Upside risks include a better-than-expected rebound in foreign visitor arrivals to Thailand, better-than-expected cost management resulting in stronger profit margins, and positive developments regarding patient referral flows under Kuwait's GOP and from Saudi Arabia, which may act as earnings catalysts.

### Exhibit 13: DCF valuation


Cost of equity assumptions (%)		Cost of debt assumptions (%)	
Risk-free rate	3.0	Pre-tax cost of debt	3.5
Market risk premium	8.5	Marginal tax rate	20.0
Stock beta	0.8		
Cost of equity, Ke	9.8	Net cost of debt, Kd	2.8
Weight applied	90.0	Weight applied	10.0
WACC			
	9.1		

DCF valuation estimate	(THB m)	(THB/share)	Comments
NPV	53,971	58.5	WACC 9.1%, Risk free rate 3%, Risk premium 8.5%
Terminal value	76,284	82.7	Terminal growth 3%
Cash & liquid assets	17,875	19.4	
Investments	130	0.1	
Debt	(139)	(0.2)	
Minorities	(438)	(0.5)	
<b>Residual ordinary equity</b>	<b>147,682.1</b>	<b>160</b>	


Source: FSSIA estimates

### Exhibit 14: One-year forward rolling P/E band



Sources: Bloomberg; FSSIA estimates

### Exhibit 15: One-year forward rolling P/BV band



Sources: Bloomberg; FSSIA estimates



Exhibit 16: Peer comparisons as of 29 July 2025

Company	BBG	Rec	Share price			Market Cap (USD m)	PE		ROE		PBV		EV/ EBITDA	
			Current	Target	Upside		25E	26E	25E	26E	25E	26E	25E	26E
			(LCY)	(LCY)	(%)		(x)	(x)	(%)	(%)	(x)	(x)	(x)	(x)
Thailand														
Bangkok Dusit Med Service	BDMS TB	BUY	21.30	31.50	47.9	10,426	20.3	18.9	16.3	16.6	3.2	3.1	12.5	11.5
Bangkok Chain Hospital	BCH TB	BUY	13.90	17.20	23.7	1,068	23.4	21.9	11.2	11.5	2.6	2.5	11.5	10.8
Bumrungrad Hospital	BH TB	HOLD	151.50	160.00	5.6	3,710	17.0	16.5	24.4	22.7	3.9	3.6	11.1	10.3
Chularat Hospital	CHG TB	BUY	1.73	2.60	50.3	600	17.5	16.4	13.7	14.3	2.4	2.3	10.0	9.2
Patrangsit Healthcare Group	PHG TB	BUY	13.50	21.0	55.6	125	12.4	10.8	15.1	16.0	1.8	1.7	5.8	5.1
Praram 9 Hospital	PR9 TB	BUY	24.10	30.0	24.5	584	22.3	20.2	14.7	14.9	3.2	2.9	14.2	12.9
Thonburi Healthcare Group	THG TB	HOLD	9.00	40.0	344.4	236	34.2	23.5	3.4	4.0	1.0	1.0	11.0	10.4
Ramkhamhaeng Hospital	RAM TB	BUY	17.40	44.0	152.9	647	15.6	13.6	7.4	8.0	1.1	1.0	19.0	17.3
Srivichai Vejvivat	VIH TB	BUY	7.45	14.0	87.9	140	12.3	13.3	10.4	8.9	1.2	1.1	6.1	7.5
Rajthanee Hospital	RJH TB	n/a	14.10	n/a	n/a	127	11.8	12.3	16.6	16.1	2.0	1.8	9.2	8.6
Ekachai Medical Care	EKH TB	n/a	5.75	n/a	n/a	142	16.9	16.2	10.3	10.1	1.7	1.7	8.7	8.5
Thailand average						17,472	18.0	16.1	13.2	13.2	2.1	2.0	10.7	10.0
Regional														
Ramsay Health Care	RHC AU	n/a	38.88	n/a	n/a	5,833	30.8	24.9	5.6	7.1	1.8	1.8	9.5	8.9
Ihh Healthcare Bhd	IHH SP	n/a	2.02	n/a	n/a	13,859	29.9	26.4	6.5	7.2	1.8	1.7	13.0	11.8
Ryman Healthcare	RYM NZ	n/a	2.49	n/a	n/a	1,506	99.6	31.1	0.6	1.8	0.6	0.5	30.2	19.1
Apollo Hospitals Enterprise	APHS IN	n/a	7,456	n/a	n/a	12,193	56.5	43.5	20.5	21.8	10.9	8.9	29.9	24.3
Kpj Healthcare Berhad	KPJ MK	n/a	2.58	n/a	n/a	2,642	29.2	26.2	14.3	14.9	4.1	3.8	14.3	13.4
Raffles Medical Group	RFMD SP	n/a	1.03	n/a	n/a	1,480	27.1	25.8	6.5	6.9	1.8	1.7	12.6	11.8
Mitra Keluarga Karyasehat	MIKA IJ	n/a	2,470	n/a	n/a	2,060	26.7	23.5	17.9	18.4	4.8	4.3	16.0	14.2
Aier Eye Hospital Group	300015 CH	n/a	13.16	n/a	n/a	17,089	29.9	25.9	17.9	18.0	5.1	4.5	17.7	15.7
Regional average						55,729	33.1	29.8	11.2	12.0	3.8	3.4	18.6	15.3
Overall average						73,201	23.9	21.9	12.4	12.7	2.8	2.6	14.0	12.2

Sources: Bloomberg; FSSIA estimates



## Financial Statements

### Bumrungrad Hospital

Profit and Loss (THB m) Year Ending Mar	2023	2024	2025E	2026E	2027E
Revenue	25,376	25,718	24,679	25,673	27,232
Cost of goods sold	(12,895)	(12,503)	(12,215)	(12,704)	(13,612)
<b>Gross profit</b>	<b>12,481</b>	<b>13,215</b>	<b>12,464</b>	<b>12,969</b>	<b>13,620</b>
Other operating income	111	145	149	154	158
Operating costs	(4,180)	(4,171)	(4,126)	(4,267)	(4,580)
<b>Operating EBITDA</b>	<b>9,509</b>	<b>10,265</b>	<b>9,572</b>	<b>10,008</b>	<b>10,512</b>
Depreciation	(1,097)	(1,077)	(1,086)	(1,151)	(1,315)
Goodwill amortisation	-	-	-	-	-
<b>Operating EBIT</b>	<b>8,412</b>	<b>9,188</b>	<b>8,487</b>	<b>8,856</b>	<b>9,198</b>
Net financing costs	139	271	205	228	290
Associates	(1)	0	0	0	0
Recurring non-operating income	(1)	0	0	0	0
Non-recurring items	88	(23)	0	0	0
<b>Profit before tax</b>	<b>8,638</b>	<b>9,436</b>	<b>8,692</b>	<b>9,084</b>	<b>9,488</b>
Tax	(1,583)	(1,604)	(1,543)	(1,717)	(1,850)
<b>Profit after tax</b>	<b>7,055</b>	<b>7,832</b>	<b>7,149</b>	<b>7,367</b>	<b>7,638</b>
Minority interests	(49)	(57)	(61)	(64)	(68)
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
<b>Reported net profit</b>	<b>7,006</b>	<b>7,775</b>	<b>7,088</b>	<b>7,303</b>	<b>7,570</b>
<b>Non-recurring items &amp; goodwill (net)</b>	<b>(88)</b>	<b>23</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Recurring net profit</b>	<b>6,918</b>	<b>7,798</b>	<b>7,088</b>	<b>7,303</b>	<b>7,570</b>
<b>Per share (THB)</b>					
Recurring EPS *	8.69	9.80	8.91	9.18	9.51
Reported EPS	8.80	9.77	8.91	9.18	9.51
DPS	3.69	5.15	5.00	5.34	5.51
Diluted shares (used to calculate per share data)	796	796	796	796	796
<b>Growth</b>					
Revenue (%)	22.5	1.3	(4.0)	4.0	6.1
Operating EBITDA (%)	33.4	8.0	(6.8)	4.5	5.0
Operating EBIT (%)	40.0	9.2	(7.6)	4.4	3.9
Recurring EPS (%)	40.0	12.7	(9.1)	3.0	3.6
Reported EPS (%)	41.9	11.0	(8.8)	3.0	3.6
<b>Operating performance</b>					
Gross margin inc. depreciation (%)	49.2	51.4	50.5	50.5	50.0
Gross margin exc. depreciation (%)	53.5	55.6	54.9	55.0	54.8
Operating EBITDA margin (%)	37.5	39.9	38.8	39.0	38.6
Operating EBIT margin (%)	33.1	35.7	34.4	34.5	33.8
Net margin (%)	27.3	30.3	28.7	28.4	27.8
Effective tax rate (%)	18.5	17.0	17.8	18.9	19.5
Dividend payout on recurring profit (%)	42.5	52.6	56.1	58.2	57.9
Interest cover (X)	(60.7)	(33.9)	(41.4)	(38.8)	(31.7)
Inventory days	10.6	11.5	11.5	11.2	11.0
Debtor days	50.8	59.5	58.9	56.6	53.4
Creditor days	33.5	35.6	37.2	36.0	35.6
Operating ROIC (%)	52.9	54.7	48.4	48.9	50.2
ROIC (%)	51.0	49.1	41.0	41.6	42.7
ROE (%)	31.8	30.4	24.4	22.7	21.5
ROA (%)	25.6	24.7	20.4	19.2	18.2
* Pre-exceptional, pre-goodwill and fully diluted					
<b>Revenue by Division (THB m)</b>					
Thai patient revenue	8,348	8,716	8,803	9,067	9,339
International patient revenue	16,948	16,919	15,793	16,523	17,809
Other revenue	80	83	83	83	83

Sources: Bumrungrad Hospital; FSSIA estimates

## Financial Statements

### Bumrungrad Hospital

Cash Flow (THB m) Year Ending Mar	2023	2024	2025E	2026E	2027E
Recurring net profit	6,918	7,798	7,088	7,303	7,570
Depreciation	1,097	1,077	1,086	1,151	1,315
Associates & minorities	-	-	-	-	-
Other non-cash items	(16)	(1,846)	61	64	68
Change in working capital	(1,021)	(56)	(116)	121	195
<b>Cash flow from operations</b>	<b>6,978</b>	<b>6,973</b>	<b>8,119</b>	<b>8,639</b>	<b>9,147</b>
Capex - maintenance	(1,617)	(1,380)	(1,481)	(1,284)	(1,634)
Capex - new investment	-	-	-	-	-
Net acquisitions & disposals	(12)	(117)	0	0	0
Other investments (net)	-	-	-	-	-
<b>Cash flow from investing</b>	<b>(1,629)</b>	<b>(1,497)</b>	<b>(1,481)</b>	<b>(1,284)</b>	<b>(1,634)</b>
Dividends paid	(2,938)	(4,101)	(3,979)	(4,253)	(4,382)
Equity finance	0	0	0	0	0
Debt finance	28	48	0	0	0
Other financing cash flows	31	(55)	0	0	0
<b>Cash flow from financing</b>	<b>(2,880)</b>	<b>(4,108)</b>	<b>(3,979)</b>	<b>(4,253)</b>	<b>(4,382)</b>
Non-recurring cash flows	-	-	-	-	-
Other adjustments	0	0	0	0	0
<b>Net other adjustments</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Movement in cash</b>	<b>2,469</b>	<b>1,368</b>	<b>2,659</b>	<b>3,103</b>	<b>3,132</b>
Free cash flow to firm (FCFF)	5,351.60	5,484.09	6,675.10	7,422.90	7,580.55
Free cash flow to equity (FCFE)	5,407.78	5,469.17	6,637.89	7,355.74	7,513.38

#### Per share (THB)

FCFF per share	5.80	5.94	7.23	8.04	8.22
FCFE per share	5.86	5.93	7.19	7.97	8.14
Recurring cash flow per share	10.05	8.83	10.35	10.71	11.25

Balance Sheet (THB m) Year Ending Mar	2023	2024	2025E	2026E	2027E
Tangible fixed assets (gross)	27,899	28,832	30,312	31,596	33,230
Less: Accumulated depreciation	(14,921)	(15,503)	(16,589)	(17,740)	(19,055)
<b>Tangible fixed assets (net)</b>	<b>12,978</b>	<b>13,328</b>	<b>13,723</b>	<b>13,856</b>	<b>14,175</b>
<b>Intangible fixed assets (net)</b>	<b>61</b>	<b>60</b>	<b>60</b>	<b>60</b>	<b>60</b>
Long-term financial assets	-	-	-	-	-
Invest. in associates & subsidiaries	13	130	130	130	130
Cash & equivalents	10,745	12,113	14,772	17,875	21,007
A/C receivable	4,408	3,982	3,982	3,982	3,982
Inventories	362	356	347	360	383
Other current assets	169	280	269	279	296
<b>Current assets</b>	<b>15,685</b>	<b>16,732</b>	<b>19,370</b>	<b>22,497</b>	<b>25,669</b>
Other assets	475	2,403	2,403	2,403	2,403
<b>Total assets</b>	<b>29,212</b>	<b>32,653</b>	<b>35,687</b>	<b>38,946</b>	<b>42,437</b>
Common equity	23,801	27,488	30,597	33,647	36,835
Minorities etc.	297	313	374	438	507
<b>Total shareholders' equity</b>	<b>24,098</b>	<b>27,801</b>	<b>30,971</b>	<b>34,086</b>	<b>37,342</b>
Long term debt	91	139	139	139	139
Other long-term liabilities	856	923	923	923	923
<b>Long-term liabilities</b>	<b>947</b>	<b>1,062</b>	<b>1,062</b>	<b>1,062</b>	<b>1,062</b>
A/C payable	1,078	1,149	1,119	1,161	1,236
Short term debt	0	0	0	0	0
Other current liabilities	3,089	2,641	2,534	2,636	2,796
<b>Current liabilities</b>	<b>4,167</b>	<b>3,790</b>	<b>3,653</b>	<b>3,798</b>	<b>4,033</b>
<b>Total liabilities and shareholders' equity</b>	<b>29,212</b>	<b>32,653</b>	<b>35,687</b>	<b>38,946</b>	<b>42,437</b>
Net working capital	772	828	944	824	629
Invested capital	14,299	16,750	17,261	17,273	17,397

\* Includes convertibles and preferred stock which is being treated as debt

#### Per share (THB)

Book value per share	29.91	34.54	38.45	42.28	46.29
Tangible book value per share	29.83	34.47	38.37	42.21	46.21

#### Financial strength

Net debt/equity (%)	(44.2)	(43.1)	(47.2)	(52.0)	(55.9)
Net debt/total assets (%)	(36.5)	(36.7)	(41.0)	(45.5)	(49.2)
Current ratio (x)	3.8	4.4	5.3	5.9	6.4
CF interest cover (x)	(38.0)	(19.2)	(31.4)	(31.2)	(24.9)

Valuation	2023	2024	2025E	2026E	2027E
<b>Recurring P/E (x) *</b>	<b>17.4</b>	<b>15.5</b>	<b>17.0</b>	<b>16.5</b>	<b>15.9</b>
<b>Recurring P/E @ target price (x) *</b>	<b>18.4</b>	<b>16.3</b>	<b>18.0</b>	<b>17.4</b>	<b>16.8</b>
Reported P/E (x)	17.2	15.5	17.0	16.5	15.9
Dividend yield (%)	2.4	3.4	3.3	3.5	3.6
Price/book (x)	5.1	4.4	3.9	3.6	3.3
Price/tangible book (x)	5.1	4.4	3.9	3.6	3.3
EV/EBITDA (x) **	11.6	10.6	11.1	10.3	9.5
EV/EBITDA @ target price (x) **	12.3	11.3	11.8	11.0	10.2
EV/invested capital (x)	7.7	6.5	6.2	6.0	5.8

\* Pre-exceptional, pre-goodwill and fully diluted \*\* EBITDA includes associate income and recurring non-operating income

Sources: Bumrungrad Hospital; FSSIA estimates

# Bumrungrad Hospital PCL (BH TB)

## FSSIA ESG rating


**51.21 /100**

### Exhibit 17: FSSIA ESG score implication

Rating	Score	Implication
★★★★★	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
★★★★★	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
★★★	>39-59	<b>Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.</b>
★★	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
★	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Sources: FSSIA estimates

### Exhibit 18: ESG – peer comparison

	FSSIA ESG score	Domestic ratings						Global ratings					Bloomberg		
		DJSI	SET ESG	ESG Rating	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94
BCH	39.71	--	--	--	4.00	5.00	Certified	High	48.21	--	--	27.19	18.00	3.52	47.60
BDMS	74.00	Y	Y	Y	5.00	4.00	--	Medium	61.06	AA	34.00	59.83	72.00	3.45	58.92
BH	51.21	--	--	--	4.00	4.00	--	Medium	64.29	A	29.00	59.03	27.00	5.08	47.79
CHG	38.25	--	--	--	4.00	5.00	--	High	55.35	--	--	59.57	21.00	2.34	50.24
PR9	54.08	--	Y	Y	5.00	5.00	Certified	High	71.12	--	--	62.39	--	2.43	37.90
PRINC	18.00	--	--	--	4.00	4.00	Certified	--	--	--	--	--	--	--	--
RAM	11.75	--	--	--	3.00	--	--	High	--	--	--	--	--	--	--
THG	18.75	--	--	--	5.00	5.00	--	High	--	--	--	--	--	--	--
VIBHA	20.88	--	--	--	4.00	3.00	Declared	High	--	--	--	--	17.00	--	--

Sources: [SETTRADE.com](https://www.settrade.com); FSSIA's compilation

### Exhibit 19: ESG score by Bloomberg

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
<b>ESG financial materiality scores - ESG score</b>	<b>0.85</b>	<b>1.30</b>	<b>1.60</b>	<b>1.49</b>	<b>1.73</b>	<b>3.35</b>	<b>3.58</b>	<b>5.08</b>
BESG environmental pillar score	0.00	1.75	1.75	1.75	1.75	3.21	3.73	3.73
BESG social pillar score	0.18	0.18	0.38	0.38	0.85	3.19	3.25	6.43
BESG governance pillar score	3.25	3.57	4.35	3.81	3.55	3.73	4.07	3.97
<b>ESG disclosure score</b>	<b>31.24</b>	<b>32.94</b>	<b>35.78</b>	<b>35.78</b>	<b>36.40</b>	<b>47.68</b>	<b>47.79</b>	<b>47.79</b>
Environmental disclosure score	0.42	5.53	8.91	8.91	9.76	35.43	35.76	35.76
Social disclosure score	12.03	12.03	17.17	17.17	18.20	26.39	26.39	26.39
Governance disclosure score	81.10	81.10	81.10	81.10	81.10	81.10	81.10	81.10
<b>Environmental</b>								
Emissions reduction initiatives	No	No	No	No	No	Yes	Yes	Yes
Climate change policy	No	No	No	No	No	Yes	Yes	Yes
Climate change opportunities discussed	No	No	No	No	No	No	No	No
Risks of climate change discussed	No	No	No	No	No	No	Yes	Yes
GHG scope 1	--	--	--	--	--	--	--	--
GHG scope 2 location-based	--	--	--	--	--	--	--	--
GHG Scope 3	--	--	--	--	--	--	--	--
Carbon per unit of production	--	--	--	--	--	--	--	--
Biodiversity policy	No	No	No	No	No	No	No	No
Energy efficiency policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Total energy consumption	--	0	0	0	0	0	0	0
Renewable energy use	--	--	--	--	--	--	--	--
Electricity used	--	--	--	--	--	--	--	--
Fuel used - natural gas	--	--	--	--	--	--	--	--

Sources: Bloomberg; FSSIA's compilation

**Exhibit 20: ESG score by Bloomberg (cont.)**

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
Fuel used - crude oil/diesel	No	No	No	No	No	No	No	No
Waste reduction policy	No	No	No	No	No	Yes	Yes	Yes
Hazardous waste	—	—	—	—	—	—	—	—
Total waste	—	—	—	—	—	—	—	—
Waste recycled	—	—	—	—	—	—	—	—
Waste sent to landfills	—	—	—	—	—	—	—	—
Environmental supply chain management	No	No	No	No	No	Yes	Yes	Yes
Water policy	No	No	No	No	Yes	Yes	Yes	Yes
Water consumption	—	—	—	—	—	—	—	—
<b>Social</b>								
Human rights policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Policy against child labor	No	No	No	No	Yes	Yes	Yes	Yes
Quality assurance and recall policy	No	No	No	No	No	Yes	Yes	Yes
Consumer data protection policy	No	No	No	No	No	Yes	Yes	Yes
Equal opportunity policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Gender pay gap breakout	No	No	No	No	No	No	No	No
Pct women in workforce	—	—	—	—	—	—	—	—
Pct disabled in workforce	—	—	—	—	—	—	—	—
Business ethics policy	No	No	No	No	No	Yes	Yes	Yes
Anti-bribery ethics policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Health and safety policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Lost time incident rate - employees	—	—	—	—	—	—	—	—
Total recordable incident rate - employees	—	—	—	—	—	—	—	—
Training policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Fair remuneration policy	No	No	No	No	No	No	No	No
Number of employees – CSR	—	—	3,984	3,980	4,088	3,782	3,455	4,219
Employee turnover pct	—	—	—	—	—	7	7	8
Total hours spent by firm - employee training	—	—	247,805	268,252	283,707	207,353	195,380	234,480
Social supply chain management	No	No	No	No	No	Yes	Yes	Yes
<b>Governance</b>								
<b>Board size</b>	<b>11</b>	<b>11</b>	<b>11</b>	<b>11</b>	<b>10</b>	<b>10</b>	<b>11</b>	<b>11</b>
<b>No. of independent directors (ID)</b>	<b>4</b>	<b>4</b>	<b>4</b>	<b>4</b>	<b>4</b>	<b>4</b>	<b>5</b>	<b>5</b>
No. of women on board	3	3	3	3	3	3	3	3
No. of non-executive directors on board	8	8	9	9	9	9	10	10
Company conducts board evaluations	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
No. of board meetings for the year	5	4	6	4	4	7	4	4
Board meeting attendance pct	91	93	97	87	88	87	95	98
Board duration (years)	3	3	3	3	3	3	3	3
Director share ownership guidelines	No	No	No	No	No	No	No	No
Age of the youngest director	42	43	49	50	51	52	27	28
Age of the oldest director	75	75	78	79	79	80	78	79
<b>No. of executives / company managers</b>	<b>7</b>	<b>6</b>	<b>6</b>	<b>6</b>	<b>4</b>	<b>4</b>	<b>4</b>	<b>5</b>
No. of female executives	1	2	2	3	3	3	3	3
Executive share ownership guidelines	No	No	No	No	No	No	No	No
<b>Size of audit committee</b>	<b>3</b>	<b>3</b>	<b>3</b>	<b>3</b>	<b>3</b>	<b>3</b>	<b>4</b>	<b>4</b>
No. of ID on audit committee	3	3	3	3	3	3	4	4
Audit committee meetings	4	4	4	5	5	4	4	4
Audit meeting attendance %	100	92	92	87	100	100	87	100
<b>Size of compensation committee</b>	<b>3</b>	<b>3</b>	<b>3</b>	<b>3</b>	<b>3</b>	<b>3</b>	<b>3</b>	<b>3</b>
No. of ID on compensation committee	1	1	1	1	1	1	1	1
No. of compensation committee meetings	1	1	5	3	2	2	3	3
Compensation meeting attendance %	100	100	100	100	100	83	100	100
<b>Size of nomination committee</b>	<b>3</b>	<b>3</b>	<b>3</b>	<b>3</b>	<b>3</b>	<b>3</b>	<b>3</b>	<b>3</b>
No. of nomination committee meetings	1	1	5	3	2	2	3	3
Nomination meeting attendance %	100	100	100	100	100	83	100	100
<b>Sustainability governance</b>								
Verification type	No	No	No	No	No	No	No	No

Sources: Bloomberg; FSSIA's compilation

## Disclaimer for ESG scoring

ESG score	Methodology	Rating																				
The Dow Jones Sustainability Indices (DJSI) By S&P Global	The DJSI World applies a transparent, rules-based component selection process based on the companies' Total Sustainability Scores resulting from the annual S&P Global Corporate Sustainability Assessment (CSA). Only the top-ranked companies within each industry are selected for inclusion.	Be a member and invited to the annual S&P Global Corporate Sustainability Assessment (CSA) for DJSI. Companies with an S&P Global ESG Score of less than 45% of the S&P Global ESG Score of the highest scoring company are disqualified. The constituents of the DJSI indices are selected from the Eligible Universe.																				
SET ESG Ratings List (SETESG) by The Stock Exchange of Thailand (SET)	SET ESG quantifies responsibility in Environmental and Social issues by managing business with transparency in Governance, updated annually. Candidates must pass the preemptive criteria, with two crucial conditions: 1) no irregular trading of the board members and executives; and 2) free float of >150 shareholders, and combined holding must be >15% of paid-up capital. Some key disqualifying criteria include: 1) CG score of below 70%; 2) independent directors and free float violation; 3) executives' wrongdoing related to CG, social & environmental impacts; 4) equity in negative territory; and 5) earnings in red for > 3 years in the last 5 years.	To be eligible for <b>SETESG inclusion</b> , verified data must be scored at a minimum of 50% for each indicator, unless the company is a part of DJSI during the assessment year. The scoring will be fairly weighted against the nature of the relevant industry and materiality. <b>SETESG Index</b> is extended from the SET ESG Ratings companies whose 1) market capitalization > THB5b (~USD150b); 2) free float >20%; and 3) liquidity >0.5% of paid-up capital for at least 9 out of 12 months. The SETTHSI Index is a market capitalisation-weighted index, cap 5% quarterly weight at maximum, and no cap for number of stocks.																				
CG Score by Thai Institute of Directors Association (Thai IOD)	An indicator of CG strength in sustainable development, measured annually by the Thai IOD, with support from the Stock Exchange of Thailand (SET). The results are from the perspective of a third party, not an evaluation of operations.	Scores are rated in six categories: 5 for Excellent (90-100), 4 for Very Good (80-89), 3 for Good (70-79), 2 for Fair (60-69), 1 for Pass (60-69), and not rated for scores below 50. Weightings include: 1) the rights; 2) and equitable treatment of shareholders (weight 25% combined); 3) the role of stakeholders (25%); 4) disclosure & transparency (15%); and 5) board responsibilities (35%).																				
AGM level By Thai Investors Association (TIA) with support from the SEC	It quantifies the extent to which shareholders' rights and equitable treatment are incorporated into business operations and information is transparent and sufficiently disclosed. All form important elements of two out of five the CG components to be evaluated annually. The assessment criteria cover AGM procedures before the meeting (45%), at the meeting date (45%), and after the meeting (10%). <i>(The first assesses 1) advance circulation of sufficient information for voting; and 2) facilitating how voting rights can be exercised. The second assesses 1) the ease of attending meetings; 2) transparency and verifiability; and 3) openness for Q&amp;A. The third involves the meeting minutes that should contain discussion issues, resolutions and voting results.)</i>	The scores are classified into four categories: 5 for Excellent (100), 4 for Very Good (90-99), 3 for Fair (80-89), and not rated for scores below 79.																				
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	The core elements of the Checklist include corruption risk assessment, establishment of key controls, and the monitoring and developing of policies. The Certification is good for three years. <i>(Companies deciding to become a CAC certified member start by submitting a Declaration of Intent to kick off an 18-month deadline to submit the CAC Checklist for Certification, including risk assessment, in place of policy and control, training of managers and employees, establishment of whistleblowing channels, and communication of policies to all stakeholders.)</i>	The document will be reviewed by a committee of nine professionals. A passed Checklist will move for granting certification by the CAC Council approvals whose members are twelve highly respected individuals in professionalism and ethical achievements.																				
Morningstar Sustainalytics	The Sustainalytics' ESG risk rating provides an overall company score based on an assessment of how much of a company's exposure to ESG risk is unmanaged. <i>Sources to be reviewed include corporate publications and regulatory filings, news and other media, NGO reports/websites, multi-sector information, company feedback, ESG controversies, issuer feedback on draft ESG reports, and quality &amp; peer reviews.</i>	A company's ESG risk rating score is the sum of unmanaged risk. The more risk is unmanaged, the higher ESG risk is scored. <table><tr><th>NEGL</th><th>Low</th><th>Medium</th><th>High</th><th>Severe</th></tr><tr><td>0-10</td><td>10-20</td><td>20-30</td><td>30-40</td><td>40+</td></tr></table>	NEGL	Low	Medium	High	Severe	0-10	10-20	20-30	30-40	40+										
NEGL	Low	Medium	High	Severe																		
0-10	10-20	20-30	30-40	40+																		
ESG Book	The ESG score identifies sustainable companies that are better positioned to outperform over the long term. The methodology considers the principle of financial materiality including information that significantly helps explain future risk-adjusted performance. Materiality is applied by over-weighting features with higher materiality and rebalancing these weights on a rolling quarterly basis.	The total ESG score is calculated as a weighted sum of the features scores using materiality-based weights. The score is scaled between 0 and 100 with higher scores indicating better performance.																				
MSCI	MSCI ESG ratings aim to measure a company's management of financially relevant ESG risks and opportunities. It uses a rules-based methodology to identify industry leaders and laggards according to their exposure to ESG risks and how well they manage those risks relative to peers. <table><tr><td>AAA</td><td>8.571-10.000</td><td rowspan="3">Leader:</td><td rowspan="3">leading its industry in managing the most significant ESG risks and opportunities</td></tr><tr><td>AA</td><td>7.143-8.570</td></tr><tr><td>A</td><td>5.714-7.142</td></tr><tr><td>BBB</td><td>4.286-5.713</td><td rowspan="3">Average:</td><td rowspan="3">a mixed or unexceptional track record of managing the most significant ESG risks and opportunities relative to industry peers</td></tr><tr><td>BB</td><td>2.857-4.285</td></tr><tr><td>B</td><td>1.429-2.856</td></tr><tr><td>CCC</td><td>0.000-1.428</td><td>Laggard:</td><td>lagging its industry based on its high exposure and failure to manage significant ESG risks</td></tr></table>		AAA	8.571-10.000	Leader:	leading its industry in managing the most significant ESG risks and opportunities	AA	7.143-8.570	A	5.714-7.142	BBB	4.286-5.713	Average:	a mixed or unexceptional track record of managing the most significant ESG risks and opportunities relative to industry peers	BB	2.857-4.285	B	1.429-2.856	CCC	0.000-1.428	Laggard:	lagging its industry based on its high exposure and failure to manage significant ESG risks
AAA	8.571-10.000	Leader:	leading its industry in managing the most significant ESG risks and opportunities																			
AA	7.143-8.570																					
A	5.714-7.142																					
BBB	4.286-5.713	Average:	a mixed or unexceptional track record of managing the most significant ESG risks and opportunities relative to industry peers																			
BB	2.857-4.285																					
B	1.429-2.856																					
CCC	0.000-1.428	Laggard:	lagging its industry based on its high exposure and failure to manage significant ESG risks																			
Moody's ESG solutions	Moody's assesses the degree to which companies take into account ESG objectives in the definition and implementation of their strategy policies. It believes that a company integrating ESG factors into its business model and relatively outperforming its peers is better positioned to mitigate risks and create sustainable value for shareholders over the medium to long term.																					
Refinitiv ESG rating	Designed to transparently and objectively measure a company's relative ESG performance, commitment and effectiveness across 10 main themes, based on publicly available and auditable data. The score ranges from 0 to 100 on relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly. <i>(Score ratings are 0 to 25 = poor; &gt;25 to 50 = satisfactory; &gt;50 to 75 = good; and &gt;75 to 100 = excellent.)</i>																					
S&P Global	The S&P Global ESG Score is a relative score measuring a company's performance on and management of ESG risks, opportunities, and impacts compared to its peers within the same industry classification. The score ranges from 0 to 100.																					
Bloomberg	ESG Score	Bloomberg score evaluating the company's aggregated Environmental, Social and Governance (ESG) performance. The score is based on Bloomberg's view of ESG financial materiality. The score is a weighted generalized mean (power mean) of Pillar Scores, where the weights are determined by the pillar priority ranking. Values range from 0 to 10; 10 is the best.																				
Bloomberg	ESG Disclosure Score	Disclosure of a company's ESG used for Bloomberg ESG score. The score ranges from 0 for none to 100 for disclosure of every data point, measuring the amount of ESG data reported publicly, and not the performance on any data point.																				

**Rating** regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "**CG Score**"; 2) "**AGM Level**"; 3) "**Thai CAC**"; and 4) **THSI**. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Vatcharut Vacharawongsith FSS International Investment Advisory Securities Co., Ltd


The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price

Bumrungrad Hospital (BH TB)



Date	Rating	Target price	Date	Rating	Target price	Date	Rating	Target price
22-Aug-2022	BUY	235.00	09-May-2023	BUY	280.00	03-May-2024	BUY	310.00
10-Nov-2022	BUY	255.00	17-Aug-2023	BUY	300.00	07-Nov-2024	HOLD	285.00
21-Feb-2023	BUY	260.00	05-Mar-2024	BUY	305.00	24-Feb-2025	BUY	220.00

Vatcharut Vacharawongsith started covering this stock from 30-Jul-2025

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Bumrungrad Hospital	BH TB	THB 151.50	HOLD	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) higher medical fee discount promotions, leading to a weaker EBITDA margin.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 29-Jul-2025 unless otherwise stated.

## RECOMMENDATION STRUCTURE

### Stock ratings

Stock ratings are based on absolute upside or downside, which we define as  $(\text{target price}^* - \text{current price}) / \text{current price}$ .

**BUY (B).** The upside is 10% or more.

**HOLD (H).** The upside or downside is less than 10%.

**REDUCE (R).** The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

\* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

### Industry Recommendations

**Overweight.** The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

**Neutral.** The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

**Underweight.** The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

### Country (Strategy) Recommendations

**Overweight (O).** Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

**Neutral (N).** Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

**Underweight (U).** Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.